LIVE MARKET TRACKER :   BSE SENSEX   31599.76      |    NSE NIFTY 9871.50    
GLOBAL MARKETS :  NASDAQ 6370.5898   -0.8765%    |    FSI London 7301.77   +0.01%    |    NIKKEI Japan 20330.19   -0.33%
  USD GBP EUR CAD AUD INR
USD - 0.7441 0.8481 1.2373 1.2672 65.6000
GBP 1.3438 - 1.1395 1.6628 1.7026 88.1669
EUR 1.1795 0.8778 - 1.4595 1.4945 77.3502
CAD 0.8084 0.6022 0.6856 - 1.0248 53.0380
AUD 0.7893 0.5875 0.6693 0.9766 - 51.7750
INR 0.0153 0.0114 0.0129 0.0189 0.0194 -
Indian-Commodity  :  Corporate  :  Glenmark Pharmaceuticals enters into exclusive agreement with Cyndea Pharma

Glenmark Pharmaceuticals enters into exclusive agreement with Cyndea Pharma (19-Jul-2017)

Glenmark Pharmaceuticals has entered into a development, license, manufacture and commercial supply agreement with Cyndea Pharma S.L., granting exclusive rights to use their technology for developing generic, soft-gelatin capsule formulations of certain pharmaceutical products.

Under this agreement, Glenmark receives exclusive rights to the United States and Canada markets for these soft-gelatin formulations in exchange for sharing development costs and profits from future sales. In addition, the agreement provides for the companies to add further soft-gelatin product candidates for development and commercialization, as new branded, soft gelatin, capsule-based drug products become available in the marketplace.

Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is primarily focused in the areas of oncology, dermatology and respiratory.



Top News Today
Jaiprakash Associates gets nod to raise up to Rs 2,000 crore
(26-Sep-2017)

Jaiprakash Associates gets nod to raise up to Rs 2,000 croreJaiprakash Associates has received its shareholders' approval to raise up to Rs 2,000 crore through sale of securities. The special resolution was approved by the shareholders at the company's annual general......click on news to read complete article.

Panacea Biotec planning to raise Rs 250 crore
(26-Sep-2017)

Panacea Biotec planning to raise Rs 250 crorePanacea Biotec is planning to raise Rs 250 crore by way of issue of equity shares and/or other securities. In this regards, the company is conducting Postal Ballot for obtaining approval of members for......click on news to read complete article.

Novartis India gets nod for Rs 231.15 crore buyback plan
(26-Sep-2017)

Novartis India gets nod for Rs 231.15 crore buyback planNovartis India has received an approval for buyback of up to 34.5 lakh shares, accounting for about 12.26% of the existing paid up capital of the company, for up to Rs 231.15 crore. The company's board......click on news to read complete article.

International Stock News
Asian markets trade mostly lower in early deals on Tuesday
(26-Sep-2017)

Asian markets trade mostly lower in early deals on TuesdayMost of the Asian equity benchmarks are trading down in the early deals on Tuesday, following declines on Wall Street overnight, as the war of words between North Korea and the US escalated. Meanwhile,......click on news to read complete article.

US markets closed lower on North Korea's threat
(26-Sep-2017)

US markets closed lower on North KoreaThe US markets closed lower on Monday, on the back of a fresh flare up in tensions between the US and North Korea and a sharp decline in technology shares. North Korean foreign minister Ri Yong Ho, speaking......click on news to read complete article.

Asian markets trade mostly lower in early deals on Monday
(25-Sep-2017)

Asian markets trade mostly lower in early deals on MondayMost of the Asian equity benchmarks are trading down in the early deals on Monday, following the lackluster cues from Wall Street and concerns about China's economy. Investors digested election results......click on news to read complete article.

 

     
  
Recent Corporate News
 
EquityInvestmentCompany ReportsIPO
Disclaimer
By clicking on this page you accept all the terms and conditions framed by us. News made available here are for informational purpose only. While utmost care has been taken in providing the same. We claim no responsibility for its accuracy. Readers of this blog who make their decision based on the information posted here are solely responsible for their actions.